Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1995; 26:914-919
© 1995 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tsevat, J
Right arrow Articles by Lee, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsevat, J
Right arrow Articles by Lee, T.

Cost-effectiveness of captopril therapy after myocardial infarction

J Tsevat, D Duke, L Goldman, MA Pfeffer, GA Lamas, Soukup JR, KM Kuntz, and TH Lee

Section for Clinical Epidemiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

OBJECTIVES. This study sought to assess the cost-effectiveness of captopril therapy for survivors of myocardial infarction. BACKGROUND. The recent randomized, controlled Survival and Ventricular Enlargement (SAVE) trial showed that captopril therapy improves survival in survivors of myocardial infarction with an ejection fraction < or = 40%. The present ancillary study was designed to determine how the costs required to achieve this increase in survival compared with those of other medical interventions. METHODS. We developed a decision-analytic model to assess the cost-effectiveness of captopril therapy in 50- to 80-year old survivors of myocardial infarction with an ejection fraction < or = 40%. Data on costs, utilities (health-related quality of life weights) and 4-year survival were obtained directly from the SAVE trial, and long-term survival was estimated using a Markov model. In one set of analyses, we assumed that the survival benefit associated with captopril therapy would persist beyond 4 years (persistent-benefit analyses), whereas in another set we assumed that captopril therapy incurred costs but no survival benefit beyond 4 years (limited-benefit analyses). RESULTS. In the limited-benefit analyses, the incremental cost-effectiveness of captopril therapy ranged from $3,600/quality-adjusted life-year for 80-year old patients to $60,800/quality-adjusted life-year for 50-year old patients. In the persistent-benefit analyses, incremental cost-effectiveness ratios ranged from $3,700 to $10,400/quality-adjusted life-year, depending on age. The outcome was generally not sensitive to changes in estimates of variables when they were varied individually over wide ranges. In a "worst-case" analysis, incremental cost-effectiveness ratios for captopril therapy remained favorable ($8,700 to $29,200/quality-adjusted life-year) for 60- to 80-year old patients but were higher ($217,600/quality-adjusted life-year) for 50-year old patients. CONCLUSIONS. We conclude that the cost-effectiveness of captopril therapy for 50- to 80-year old survivors of myocardial infarction with a low ejection fraction compares favorably with other interventions for survivors of myocardial infarction.


This article has been cited by other articles:


Home page
Eur J Heart FailHome page
W. C. Levy, D. Mozaffarian, D. T. Linker, K. W. Kenyon, J. G.F. Cleland, M. Komajda, W. J. Remme, C. Torp-Pedersen, M. Metra, P. A. Poole-Wilson, et al.
Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials
Eur J Heart Fail, March 1, 2009; 11(3): 256 - 263.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
D A Turner, S Paul, M A Stone, A Juarez-Garcia, I Squire, and K Khunti
Cost-effectiveness of a disease management programme for secondary prevention of coronary heart disease and heart failure in primary care
Heart, December 1, 2008; 94(12): 1601 - 1606.
[Abstract] [Full Text] [PDF]


Home page
Med Decis MakingHome page
Z. Agha, R. P. Lofgren, and J. V. VanRuiswyk
Is Antibiotic Prophylaxis for Bacterial Endocarditis Cost-Effective?
Med Decis Making, May 1, 2005; 25(3): 308 - 320.
[Abstract] [PDF]


Home page
CirculationHome page
W. S. Weintraub, Z. Zhang, E. M. Mahoney, P. Kolm, J. A. Spertus, J. Caro, J. Ishak, R. Goldberg, J. Tooley, R. Willke, et al.
Cost-Effectiveness of Eplerenone Compared With Placebo in Patients With Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure
Circulation, March 8, 2005; 111(9): 1106 - 1113.
[Abstract] [Full Text] [PDF]


Home page
Med Decis MakingHome page
J. M. Mrus and J. Tsevat
Cost-Effectiveness of Interventions to Reduce Vertical HIV Transmission from Pregnant Women Who Have Not Received Prenatal Care
Med Decis Making, January 1, 2004; 24(1): 30 - 39.
[Abstract] [PDF]


Home page
ANN INTERN MEDHome page
J. M. Neuner, M. B. Hamel, R. S. Phillips, K. Bona, and M. D. Aronson
Diagnosis and Management of Adults with Pharyngitis: A Cost-Effectiveness Analysis
Ann Intern Med, July 15, 2003; 139(2): 113 - 122.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
T. R. Gildea, K. M. Shermock, M. E. Singer, and J. K. Stoller
Cost-Effectiveness Analysis of Augmentation Therapy for Severe {alpha}1-Antitrypsin Deficiency
Am. J. Respir. Crit. Care Med., May 15, 2003; 167(10): 1387 - 1392.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
T A McDonagh
Screening for left ventricular dysfunction: a step too far?
Heart, October 1, 2002; 88(90002): ii12 - 14.
[Full Text] [PDF]


Home page
Eur J Heart FailHome page
W. M. Hart, C. Rubio-Terres, F. Pajuelo, and J. R. G. Juanatey
Cost-effectiveness of the treatment of heart failure with ramipril: a Spanish analysis of the AIRE study
Eur J Heart Fail, August 1, 2002; 4(4): 553 - 558.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
B. Riegel, B. Carlson, Z. Kopp, B. LePetri, D. Glaser, and A. Unger
Effect of a Standardized Nurse Case-Management Telephone Intervention on Resource Use in Patients With Chronic Heart Failure
Arch Intern Med, March 25, 2002; 162(6): 705 - 712.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
D. C. ANGUS, A. A. MUSTHAFA, G. CLERMONT, M. F. GRIFFIN, W. T. LINDE-ZWIRBLE, T. T. DREMSIZOV, and M. R. PINSKY
Quality-adjusted Survival in the First Year after the Acute Respiratory Distress Syndrome
Am. J. Respir. Crit. Care Med., May 1, 2001; 163(6): 1389 - 1394.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
K. A. Phillips, M. G. Shlipak, P. Coxson, P. A. Heidenreich, M. G. M. Hunink, P. A. Goldman, L. W. Williams, M. C. Weinstein, and L. Goldman
Health and Economic Benefits of Increased {beta}-Blocker Use Following Myocardial Infarction
JAMA, December 6, 2000; 284(21): 2748 - 2754.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
M. W. Rich and R. F. Nease
Cost-effectiveness Analysis in Clinical Practice: The Case of Heart Failure
Arch Intern Med, August 9, 1999; 159(15): 1690 - 1700.
[Abstract] [Full Text] [PDF]


Home page
Arch Pediatr Adolesc MedHome page
J. Tsevat and U. R. Kotagal
Management of Sore Throats in Children: A Cost-effectiveness Analysis
Arch Pediatr Adolesc Med, July 1, 1999; 153(7): 681 - 688.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
The Large State Peer Review Organization Consortiu
Heart Failure Treatment With Angiotensin-Converting Enzyme Inhibitors in Hospitalized Medicare Patients in 10 Large States
Arch Intern Med, May 26, 1997; 157(10): 1103 - 1108.
[Abstract] [PDF]


Home page
CirculationHome page
K. M. Kuntz, J. Tsevat, L. Goldman, and M. C. Weinstein
Cost-effectiveness of Routine Coronary Angiography After Acute Myocardial Infarction
Circulation, September 1, 1996; 94(5): 957 - 965.
[Abstract] [Full Text]


Home page
CirculationHome page
S. C. Smith Jr
Risk-Reduction Therapy: The Challenge to Change : Presented at the 68th Scientific Sessions of the American Heart Association November 13, 1995 Anaheim, California
Circulation, June 15, 1996; 93(12): 2205 - 2211.
[Full Text]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement